Bristol-Myers Squibb Company
CELL LOCALIZATION SIGNATURE AND COMBINATION THERAPY

Abstract:

The present disclosure provides methods of identifying a subject suitable for an immuno-oncology (I-O) therapy comprising measuring the expression of one or more of STAT1, IFN.gamma., NECTIN2, and CSF1R. In some aspects, the I-O therapy comprises administering an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof to the subject.